Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio

Jazz Pharmaceuticals said on Monday it would buy privately held Actio Biosciences in a deal valued at ​up to $1.32 billion, adding an experimental treatment for ‌a rare inherited form of epilepsy that...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。